# A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome

Study · id `cardio:ct-nct05843162` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05843162](<https://clinicaltrials.gov/study/NCT05843162>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05843162

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 116 participants.

## Technical summary

Registry record NCT05843162. Randomized; no masking; primary purpose treatment. Start 2023-06-01 (anticipated); primary completion 2023-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 116 participants (planned count; ClinicalTrials.gov record NCT05843162, source copy `cardio:ctgov-nct05843162-2023-05-06`, retrieved 2026-10-26)
- Planned start: 2023-06-01 (anticipated) (ClinicalTrials.gov record NCT05843162, source copy `cardio:ctgov-nct05843162-2023-05-06`, retrieved 2026-10-26)
- Primary completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05843162, source copy `cardio:ctgov-nct05843162-2023-05-06`, retrieved 2026-10-26)
- Completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05843162, source copy `cardio:ctgov-nct05843162-2023-05-06`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05843162-2023-05-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
- Acronym: PRISTINE
- Condition: Essential Hypertension
- Condition: Metabolic Syndrome
- Intervention (Drug): Telmisartan
- Intervention (Drug): Losartan
- Lead sponsor: Chong Kun Dang Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Telmisartan (`cardio:telmisartan`)
- Registry intervention name matches this record: Losartan (`cardio:losartan`)
- Registry intervention is a member of this class by a sourced record link: Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- Registry lists this organization as the lead sponsor: Chong Kun Dang Pharmaceutical (`cardio:org-chong-kun-dang-pharmaceutical`)

## Provenance

Content hash: 34c9cc35a6049ce0b422b3b46b6b6945be74d3057544f77ed9c7fff841c0855b
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
